Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) EBIT: 2016-2025

Historic EBIT for Assembly Biosciences (ASMB) over the last 9 years, with Sep 2025 value amounting to -$10.9 million.

  • Assembly Biosciences' EBIT rose 0.67% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.4 million, marking a year-over-year increase of 6.44%. This contributed to the annual value of -$45.4 million for FY2024, which is 29.74% up from last year.
  • As of Q3 2025, Assembly Biosciences' EBIT stood at -$10.9 million, which was up 1.89% from -$11.1 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' EBIT ranged from a high of -$9.9 million in Q1 2025 and a low of -$62.9 million during Q4 2021.
  • For the 3-year period, Assembly Biosciences' EBIT averaged around -$12.9 million, with its median value being -$11.5 million (2024).
  • Its EBIT has fluctuated over the past 5 years, first crashed by 459.72% in 2021, then soared by 45.15% in 2024.
  • Over the past 4 years, Assembly Biosciences' EBIT (Quarterly) stood at -$62.9 million in 2021, then reached -$12.6 million in 2023, then climbed by 8.12% to -$11.5 million in 2024, then climbed by 0.67% to -$10.9 million in 2025.
  • Its EBIT stands at -$10.9 million for Q3 2025, versus -$11.1 million for Q2 2025 and -$9.9 million for Q1 2025.